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Summary
Che-1 is a RNA polymerase II-binding protein involved in the transcription of E2F target genes and induction of cell prolifer-
ation. Here we show that Che-1 contributes to DNA damage response and that its depletion sensitizes cells to anticancer
agents. The checkpoint kinases ATM/ATR and Chk2 interact with Che-1 and promote its phosphorylation and accumulation
in response to DNA damage. These Che-1 modifications induce a specific recruitment of Che-1 on the TP53 and p21 pro-
moters. Interestingly, it has a profound effect on the basal expression of p53, which is preserved following DNA damage.
Notably, Che-1 contributes to the maintenance of the G2/M checkpoint induced by DNA damage. These findings identify
a mechanism by which checkpoint kinases regulate responses to DNA damage.Introduction
InDNAdamage response (DDR), eukaryotic cells activatecheck-
point pathways to arrest the cell cycle and facilitateDNA repair or
induce apoptosis (Hoeijmakers, 2001; Bartek and Lukas, 2001;
Zhou and Elledge, 2000). Ataxia-telangiectasia mutated (ATM)
and checkpoint kinases Chk1 and Chk2 are early and key medi-
ators of DDR through activation of an increasing number of sub-
strates (Shiloh, 2003; Kastan and Lim, 2000; Bartek and Lukas,
2003) such as p53, NBS1, BRCA1, MDM2, Cdc25A, Cdc25C,
and E2F1 (Shiloh, 2003; Kastan and Lim, 2000; Bartek and
Lukas, 2003). The relevance of these kinases in themaintenance
of genome integrity is clearly indicated by the severe human
genetic disorders and the predisposition to cancer associatedCANCER CELL 10, 473–486, DECEMBER 2006 ª2006 ELSEVIER INC. DOwith defects in these proteins (Hoeijmakers, 2001; van Gent
et al., 2001; Khanna and Jackson, 2001). In addition, DDR was
identified as a potent anticancer barrier in human precancerous
lesions (Bartkova et al., 2005; Gorgoulis et al., 2005).
p53 is a tumor suppressor mainly involved in the transcrip-
tional regulation of a large number of growth-arrest- and apo-
ptosis-related genes (Levine, 1997; el-Deiry et al., 1992). Upon
genotoxic damage, p53 contributes to cell-cycle arrest at the
G1/S and/or G2/M checkpoints through diverse mechanisms
(Wahl and Carr, 2001). To exert these functions, p53 that is con-
stitutively expressed at very low levels and in an inactive confor-
mation must be induced and activated (Ryan et al., 2001; Prives
and Hall, 1999). These events are thought to depend mainly on
posttranslational modifications that include phosphorylation byS I G N I F I C A N C E
The DNA-damage-signaling pathway is a highly conserved response to genotoxic stresses. In this pathway, ATM/ATR are generally
sensors of DNA damage, but, together with the checkpoint kinases Chk1 and Chk2, they also function as response effectors by phos-
phorylation of key substrates, such as p53, BRCA1, and NBS1. In particular, p53 phosphorylation leads to protein accumulation and
activation, which in turn promotes cell-cycle arrest or apoptosis. Here we describe a mechanism by which ATM/ATR and Chk2 can
regulate p53 expression through Che-1 phosphorylation and stabilization. Essentially, Che-1 inhibition potentiates the cytotoxicity of
anticancer drugs, thus suggesting Che-1 as a possible therapeutic target to increase the efficacy of DNA-damaging drugs.I 10.1016/j.ccr.2006.10.012 473
A R T I C L EFigure 1. DNA damage induces Che-1 protein
stabilization
Aand B:WB of TCEs from HCT116 cells exposed to
0.1 (A) or 1 mM (B) Dox.
C: WB analysis with the indicated Abs of HCT116
cells explanted from untreated or DDP- or Dox-
treated (10 mg/kg) nude mice.
D: WB for the indicated protein of TCEs from
p53+/+ or p532/2 MEFs treated with 1 mM Dox for
the indicated times.
E:WB of TCEs from HCT116 cells incubated with or
without 1 mM Dox for 2 hr. 20 mM chx was then
added for the indicated times.
F: Top: HCT116 cells treated with or without 1 mM
Dox for 1 hr were incubated with 35S methionine
for 20 min. TCEs were collected at the indicated
times and immunoprecipitated with anti-Che-1
Ab. Bottom: the same gel blotted and incu-
bated with anti-Che-1 Ab.
G: Top: autoradiography of immunoprecipi-
tates with anti-Che-1 Ab from HCT116 cells in-
cubated with 32P inorganic orthophosphate and
treated with or without 1 mM Dox for 2 hr. Bottom:
the same gel blotted and incubated with anti-
Che-1 Ab.
H: HCT116 cells were incubated with 1 mM Dox
with or without 10 mM MG132 for 2 hr. TCEs were
incubated for 30 min with CIAP and immuno-
blotted with anti-Che-1 or anti-a-tubulin Abs.ATM/ATR, Chk1, and Chk2 kinases, at least upon certain stress
stimuli (Banin et al., 1998; Shieh et al., 2000; Hirao et al., 2000).
However, increasing evidence supports a role for p53 regulation
also at the transcription level (Sun et al., 1995; Hellin et al., 1998;
Pei et al., 1999; Takaoka et al., 2003).
HumanChe-1 is a highly conservedRNA polymerase II (Pol II)-
binding protein that regulates gene transcription and cell prolif-
eration (Fanciulli et al., 2000; Thomas et al., 2000; Lindfors et al.,
2000; Page et al., 1999; Burgdorf et al., 2004; Bruno et al., 2002).
Che-1 interacts with Rb and affects its growth suppression ac-
tivity by interfering with the Rb-mediated recruitment of histone
deacetylase I on the promoters of E2F1-responsive genes (Fan-
ciulli et al., 2000; Bruno et al., 2002). Traube, themouse homolog
of Che-1, is essential for proliferation of preimplantation em-
bryos (Thomas et al., 2000). Despite this proproliferative role
of Che-1/Traube, we observed that Che-1 is downregulated in
several tumors compared to matching normal tissues, with an
incidence of 80% in the colon carcinomas examined (Di Padova
et al., 2003). In agreement, Che-1 overexpression caused cell-
cycle arrest in colon carcinoma cells by induction of the CDK
inhibitor p21Waf1 (p21) (Di Padova et al., 2003). The latter finding
prompted us to investigate Che-1 regulation in DDR. Here, we
show that DNA damage by different genotoxic agents is474associated with Che-1 phosphorylation and extended half-life.
These posttranslational modifications are induced by ATM and
Chk2, which phosphorylate Che-1 on specific residues and
are functionally linked to the DNA-damage-induced G2/M
checkpoint. Moreover, microarray and chromatin immunopre-
cipitation analyses show that Che-1 activates the transcription
of p53 and consequently of several p53 target genes, suggest-
ing a pathway by which ATM and Chk2 may modulate p53
levels. Finally, we show that Che-1 depletion strongly sensitizes
tumor cells to anticancer drugs, suggesting Che-1 as a possible
therapeutic target to increase the efficacy of antitumor agents.
Results
DNA damage stabilizes Che-1 protein
To investigate the involvement of Che-1 in DDR, HCT116 human
colon carcinoma cells were treated with different genotoxic
agents, including the anticancer drugs doxorubicin (Dox) and
cisplatin (DDP), UV light, or ionizing radiations (IR). Early accu-
mulation of Che-1 was detectable upon each treatment at both
sublethal (0.1mMDox; Figure 1A) and lethal (1mMDox; Figure 1B)
doses of agents, in a time- and dose-dependent manner (Fig-
ures 1A and 1B and Figures S1A, S1B, and S1C [see theCANCER CELL DECEMBER 2006
A R T I C L EFigure 2. ATM/ATR regulates Che-1
A and B: WB of TCEs from HCT116 cells treated
with the indicated drugs for 2 hr (1 mM Dox,
10 mM caffeine), and then with 20 mM chx for
an extra 2 hr.
C: HFF and AT cells were treated with or without
1 mM Dox for 2 hr, and WB was performed with
the indicated Abs.
D: TCEs from HCT116 cells treated for the indi-
cated times with 1 mM Dox were immunoprecip-
itated with anti-ATM Ab and analyzed by WB
with the indicated Abs.
E: Specific phosphorylation of Che-1 by ATM/
ATR. Flag-ATM was immunoprecipitated from
293 transfected cells and employed in an in vitro
reaction to phosphorylate GST, His-p53, and GST-
Che-1 proteins. The left panel shows Coomassie
blue staining of purified GST and 63His fusion pro-
teins (as indicated by asterisks); the right panel
depicts the 32P autoradiograph of the kinase as-
say performed with equal amounts of GST and
63His fusion proteins.
F: In vitro phosphorylation of Che-1 at Ser187. GST-
Che-1 or the GST-Che-1S187A mutant was used as
substrate for ATM kinase assay. The upper and
middle panels depict ATM and Che-1 32P auto-
radiographs, and the lower panel shows Coo-
massie blue stain of purified GST-Che-1 proteins.
G: HCT116 cells were transfected with Myc-Che-1
or Myc-Che-1S187A mutant. At 48 hr posttransfec-
tion, cells were treated as described in A, and
TCEswere analyzedby WB with the indicatedAbs.Supplemental Data available with this article online]). In agree-
ment,Che-1accumulated invivo inHCT116cells injected innude
mice and treatedwith drugs (Figure 1C). In addition, Che-1 accu-
mulation was detectable in primary mouse embryo fibroblasts
(MEFs) (Figure 1D, left panel) and preceded the expected p53
upregulation in each tested condition (Figures 1A and 1B and
data not shown). Thus, to assesswhether Che-1 accumulation is
independent of p53, MEFs from wild-type (WT) (p53+/+) and KO
(p532/2) mice were treated with Dox. Comparable induction of
Che-1 was detected in the two populations (Figure 1D), indicat-
ing that Che-1 levels are increased in DDR independently of p53.
To identify the mechanism(s) of Che-1 accumulation, Dox-
treated and untreated HCT116 cells were employed. No differ-
ences were observed in Che-1 mRNA levels and Che-1 pro-
moter activity, as assessed by northern blotting and luciferase
reporter assay, respectively (data not shown). In contrast, Dox
treatment strongly increased the levels of transfected Myc-
taggedChe-1 (Myc-Che-1), whose expression is driven by a het-
erologous promoter (data not shown), suggesting the presence
of a posttranslational regulation. Thus, we tested the half-life of
Che-1 in Dox-treated and untreated HCT116 cells either in the
presence of the translation inhibitor cycloheximide (chx), or by
pulse-chase of 35S-methionine metabolic labeled cells. The
half-life of Che-1 was strongly increased (from <2 hr to >4 hr)
by Dox treatment (Figures 1E and 1F), indicating that DDR
induces Che-1 accumulation by promoting its stability. In addi-
tion, cell treatment with the proteasome inhibitor MG132
increased the half-life of Che-1 to a similar extent as Dox-
treatment (Figure S1D), suggesting the involvement of the
proteasome system in the regulation of Che-1 stability. Taken
together, these data show that DDR is associated with a p53-
independent, posttranslational modification-driven stabilization
of Che-1.CANCER CELL DECEMBER 2006DNA-damage-induced phosphorylation of Che-1
counteracts its degradation
DDR is regulated, at the early steps, by a series of kinases that
activate downstream targets, such as p53 and E2F1, through
their phosphorylation and subsequent stabilization (Banin
et al., 1998; Hirao et al., 2000). Thus, we evaluated whether
Che-1 was phosphorylated in DDR. Che-1 was immunoprecip-
itated from 32P-orthophosphate-labeled HCT116 treated or not
with Dox. Upon normalization of the amount of the immuno-
precipitated proteins (Figure 1G, lower panel), a strong increase
of Che-1 phosphorylation was detected after Dox treatment
(Figure 1G, upper panel), showing that Che-1 can be phosphor-
ylated in vivo at least in this stressing condition.
To test whether Dox-induced phosphorylation of Che-1 is
linked to its stabilization, total cell extracts (TCEs) were pre-
pared from Dox-treated HCT116 cells in the presence of ATP
and glycerol to preserve the integrity of the 26S proteasome
(Canu et al., 2000). TCEs were subsequently incubated with
calf intestinal alkaline phosphatase (CIAP) in the presence or ab-
sence of MG132 and analyzed by western blotting (WB). CIAP
treatment substantially reduced Dox-induced stabilization of
Che-1, but MG132 prevented this reduction (Figure 1H), sug-
gesting that phosphorylation is involved in Che-1 stabilization.
Che-1 is an ATM substrate
ATM and ATR are ser/thr kinases that phosphorylate several
critical checkpoint proteins in DDR (Shiloh, 2003; Kastan and
Lim, 2000). Thus, we tested whether these kinases are involved
in Che-1 accumulation by using the specific inhibitor caffeine
(Sarkaria et al., 1999). Preincubation of cells with caffeine inter-
fered with Dox-induced accumulation of Che-1 (Figure 2A). This
effect was dependent on caffeine-mediated inhibition of Che-1
stabilization, as shown by the absence of Che-1 accumulation475
A R T I C L EFigure 3. Chk2 phosphorylates Che-1
A: WB of HCT116 and HCT15 cells treated with or
without 1 mM Dox.
B: HCT116 and HCT15 cells or HCT15 cells stably
expressing either WT or kd Chk2 were treated with
or without 1 mM Dox for 2 hr and then with 2 mM
chx for an extra 2 hr. TCEs were analyzed as in A.
C: TCEs from HCT116 cells treated with 1 mM Dox
for the indicated times were immunoprecipi-
tated with anti-Chk2 Ab and analyzed by WB
with the indicated Abs.
D: Specific phosphorylation of Che-1 by Chk2.
Myc-Chk2 or Myc-Chk2 kd were immunoprecipi-
tated from transfected 293 cells and employed in
in vitro reactions to phosphorylate GST, His-p53,
and GST-Che-1 proteins. The left panel shows
Coomassie blue staining of purified recombinant
proteins (as indicated by asterisks), the middle
panel depicts the 32P autoradiograph of the
same gel, and the right panel shows an in vitro ki-
nase assay performed with Chk2 and Chk2 kd.
E: GST-Che-1 recombinant proteins were used as
substrates for a Chk2 kinase assay in vitro. The up-
per panel depicts Chk2 and Che-1 32P autoradio-
graphs, and the lower panel shows the blot of the
gel analyzed with anti-Che-1 Ab.
F: HCT116 cells were transfected with Myc-Che-1
or the Myc-Che-1S3A mutant. At 48 hr posttrans-
fection, cells were treated with Dox and chx as in-
dicated, and WB was performed with the
indicated Abs.
G: Specific phosphorylation of Che-1 by Chk1.
Flag-Chk1 was immunoprecipitated from 293
transfected cells and used to phosphorylate
GST, GST-p53, and GST-Che-1 proteins in in vitro
reaction. The left panel shows Coomassie blue
staining of purified recombinant proteins (as indi-
cated by asterisks), and the right panel depicts
the 32P autoradiograph of the same gel.upon Dox treatment in the presence of chx (Figure 2B). A direct
role of ATM inDox-induced stabilization of Che-1was confirmed
by its severe impairment in human fibroblasts from ataxia telan-
giectasia (AT) patients when matched up to normal human fetal
fibroblasts (HFF) (Figure 2C). Comparable results were obtained
by depleting ATM with small interfering RNA (siRNA) in HCT116
cells (Figure S2A), supporting a role for ATM in DNA-damage-in-
duced Che-1 accumulation.
Next, using TCEs from HCT116 cells, we tested whether the
endogenous ATM and Che-1 proteins can physically interact.
Though low levels of Che-1 coprecipitated with ATM in control
cells, increasingamountsofChe-1werecoprecipitatedafterDox
treatment (Figure 2D), indicating that the two proteins belong to
a same complex and that Dox treatment increases the presence
of Che-1 in this complex. We then examined whether ATM
directly phosphorylates Che-1 by in vitro kinase assays. Re-
combinant GST-Che-1 was used as substrate for Flag-ATM im-
munoprecipitated from 293 cells. The presence of a specific
phosphorylation signal onGST-Che-1 andHis-p53 positive con-
trol, but not on GST alone (Figure 2E), indicated that Che-1 can
be phosphorylated by ATM in vitro. Similar results were obtained
by performing the kinase assaywith ATR (Figure S2B), indicating
that Che-1 can also be a target for this kinase. The absence of
Che-1phosphorylationby thekinase-dead formsofATMandATR
demonstrated the specificity of these reactions (Figure S2B).
Three putative ATM/ATR consensus sites (Kim et al., 1999;
O’Neill et al., 2000) are present in Che-1 at residues Ser187,
Thr391, and Thr407. To identify the target(s), GST fusion476polypeptides covering the whole Che-1 protein were used as
substrates in in vitro kinase assays with Flag-ATM. Only the
GST-164-270 polypeptide carrying Ser187 was phosphorylated
by ATM (Figure S2C). In addition, substitution of Che-1 Ser187
with an alanine (Che-1S187A) prevented Che-1 phosphorylation
by ATM (Figure 2F), supporting this residue as an ATM-target
site.
To evaluate whether this phosphorylation site plays a role in
Che-1 stabilization, we compared the expression levels of exog-
enous Myc-Che-1 and Myc-Che-1S187A proteins in HCT116
cells. The Dox-induced accumulation of Che-1 was strongly re-
duced, though not completely abolished, in theMyc-Che-1S187A
mutant (Figure 2G), indicating that Che-1 Ser187 is phosphory-
lated by ATM/ATR in DDR and that this phosphorylation contrib-
utes to increase Che-1 stability.
Che-1 is a Chk2 substrate
The residual stabilization capacity of the Myc-Che-1S187A mu-
tant suggests that other kinases might be involved in Che-1 sta-
bilization. Since we previously identified Che-1 in a yeast two-
hybrid screen using Chk2 as bait (D.L. and L.Z., unpublished
data), we tested whether this kinase is also involved in Che-1
regulation. Dox-induced Che-1 accumulation and stabilization
were assessed in Chk2-proficient HCT116 and Chk2-defective
HCT15 cells (Bell et al., 1999). Although Che-1 levels increased
in both cell lines, most likely due to Chk1 kinase operating in a
redundant manner (Figure 3A), reduced Che-1 stabilization
was observed in HCT15 cells (Figure 3B), which was rescuedCANCER CELL DECEMBER 2006
A R T I C L EFigure 4. Che-1 is stabilized by ATM/ATR and
Chk2 phosphorylation
A: Top: autoradiography of immunoprecipitates
with anti-Myc Ab from HCT116 cells transfected
with Myc-Che-1 or the Myc-Che-1S4A mutant, in-
cubated with 32P ortophosphate, and treated
with 1 mM Dox for 2 hr. Bottom: WB of the same
gel with anti-Myc Ab.
B: HCT116 cells transfected with Myc-Che-1 or
the indicated Che-1 mutants. At 48 hr posttrans-
fection, cells were treated with 1 mM Dox and
20 mM chx for the indicated times and analyzed
by WB with the indicated Abs.
C: WB of HCT116 and HCT15 cells treated with
the indicated drugs for 2 hr (1 mM Dox, 10 mM
caffeine).
D: AT fibroblasts transfected with nonspecific
control pool (control) or with SMART pool Chk2
siRNAs. At 48 hr posttransfection, cells were
treated with 1 mM Dox and TCEs analyzed by
WB with the indicated Abs.
E: TCEs from HCT116 cells untransfected (left) or
transfected with Myc-Che-1 or Myc-Che-1S4A
mutant (right) and treated with 1 mM Dox for
1 hr were analyzed by WB with anti-P-Ser141
Ab (top panels). The same filters were assessed
with anti-Che-1 (bottom left) or anti-Myc (bottom
right) Abs. Bottom panel: Che-1 phosphopep-
tide sequence to produce the phospho-specific
antiserum.by restoring the expression of wild-type, but not of kinase-dead,
Chk2 (Figure 3B). Compatible results were obtained in HCT116
cells upon Chk2 depletion by siRNA (Figure S2D), strongly sug-
gesting that Chk2 contributes to Che-1 half-life regulation.
Next, we performed a series of experiments similar to those
described above for the ATM/Che-1 interaction to test the phys-
ical and functional interaction between Che-1 and Chk2. Coim-
munoprecipitation of endogenous proteins was performed in
untreated and Dox-treated HCT116 cells with anti-Chk2 Ab. A
strong interaction between Che-1 and Chk2 was detected after
DNA damage (Figure 3C) and confirmed in U2OS cells trans-
fected with Myc-Che-1 and Flag-Chk2 and treated with Dox or
IR (Figure S2E).
To evaluate the ability of Chk2 to phosphorylate Che-1, re-
combinant GST-Che-1 was used as substrate for immunopre-
cipitated Myc-Chk2 in in vitro kinase assay. As shown in Fig-
ure 3D, Che-1 was phosphorylated by Chk2 as efficiently as
p53. Three putative Chk2 phosphorylation sites (Stevens et al.,
2003) are present in Che-1 at resides Ser141, Ser474, and
Ser508. Thus, we performed in vitro Chk2 kinase assays utilizing
the GST-Che-1 fusion peptides spanning these residues as sub-
strates. Both GST-84-173 and GST-471-558 were phosphory-
lated (Figure S3F), suggesting that Chk2 targets more than one
residue on Che-1. Accordingly, the phosphorylation of Che-1
with double Ser-to-Ala mutations at residues 141 and 474
(Myc-Che-1S141A/S474A) or 141 and 508 (Myc-Che-1S141A/S508A)
was markedly attenuated, whereas the phosphorylation of
Che-1 with a triple mutation (Myc-Che-1S3A) was abrogated
(Figure 3E), and Dox treatment almost failed to increase the
half-life of this mutant (Figure 3F). Taken together, these results
indicate that Chk2 phosphorylates Che-1 and this phosphoryla-
tion contributes to increase Che-1 stability.
Since Chk1 and Chk2 share most of their known sub-
strates (Bartek and Lukas, 2003), we tested whether Chk1 canCANCER CELL DECEMBER 2006phosphorylate Che-1. A kinase assay was performed with
immunoprecipitated Flag-Chk1 from transfected 293 cells.
GST-Che-1 was strongly phosphorylated by Chk1 (Fig-
ure 3G), suggesting that this kinase might also affect Che-1
stabilization.
ATM and Chk2 cooperate to stabilize Che-1
The above observations suggest that ATM/ATR andChk2 are re-
quired for increasing Che-1 stability in DDR. To test this hypoth-
esis, a Che-1mutant lacking both ATM and Chk2 phospho-sites
(Myc-Che-1S4A) was constructed and tested for in vivo phos-
phorylation and stability. After Dox treatment of 32P-orthophos-
phate-labeled HCT116 cells, the wild-type Myc-Che-1 was
strongly phosphorylated while the Myc-Che-1S4A mutant was
not (Figure 4A), indicating that the S4Amutant is no longer phos-
phorylated in vivo upon DNA damage. Next, we compared the
half-lives of the different Che-1 mutants by WB in the presence
of Chx. A progressive reduction of the half-life was detectable
with the ATM/ATR-unphosphorylatable Che-1S187A single mu-
tant being the most stable, though less than the wild-type Che-
1 and the Che-1S4A, which are completely resistant to stabiliza-
tion (Figure 4B, compare the uppermost and lowest lanes of
Figure 4B). In agreement, inhibition of ATM/ATR activity by caf-
feine in Chk2-defective HCT15 cells and Chk2 depletion by
siRNA in ATM2/2 cells completely abrogated the Dox-induced
Che-1 stabilization (Figures 4C and 4D).
To evaluate whether endogenous Che-1 is phosphorylated
at these sites in vivo, we produced an anti-phospho-specific
peptide antiserum directed against the phosphorylated Ser141
(P-Ser141; Figure 4E). The other three sites could not be em-
ployed for technical reasons (for details, see Experimental
Procedures). The anti-P-Ser141 Ab strongly reacted with Che-1
after Dox treatment and did not show any reactivity on the Myc-
Che-1S4A mutant (Figure 4E).477
A R T I C L EFigure 5. Che-1 activates p53 transcription
A: Equal amounts of RNA (RNA input) from NIH3T3
cells uninduced (2Tet) and induced (+Tet) to
express Che-1 were analyzed by RT-PCR (25–30
cycles) for expression of the indicated genes.
The RT control lanes represent RT-PCR in the ab-
sence of reverse transcription.
B and C: HCT116 cells were transiently trans-
fected with 1 mg of the indicated luciferase re-
porters and, where indicated, with increasing
amounts of Myc-Che-1 expression vector. Lower
panels: Myc-Che-1 expression by WB with anti-
Myc Ab. Error bars indicate SD.
D: HCT116 cells were transiently transfected with
siRNA GFP (siGFP) or siRNA Che-1 (siChe-1) and
48 hr later treated, where indicated, with 1 mM
Dox for 2 hr. Top: RT-PCR evaluates the expression
of the indicated genes. Bottom: WB with the
indicated Abs.
E:WB with the indicated Abs of TCEs from HCT116
transfected as in D and treated 48 hr later with
1 mM Dox for the indicated times.
F: WB of HCT116 cells untransfected (control) or
transfected with Myc-Che-1 or Myc-Che-1S4A
mutant and treated or not with 1 mM Dox for 2 hr.Che-1 activates p53 transcription
The data described above demonstrate that DDR is associated
with ATM/ATR- and Chk2-mediated accumulation of Che-1.
SinceChe-1 is aRNAPol II-binding protein involved in gene tran-
scription, to understand the biological relevance of Che-1 accu-
mulation in DDR, we used high-density Affimetrix microarrays.
MessengerRNAwasextracted fromNIH3T3cells that condition-
ally express human Che-1 cDNA in a tetracycline (Tet)-regulated
manner (Bruno et al., 2002). Both noninduced and Tet-induced
cells were employed. Transcriptional profiles were compared
and computational analyses performed to identify genes regu-
lated only after Che-1 overexpression. In agreement with previ-
ous results (Bruno et al., 2002), several E2F target genes (Muller478et al., 2001)were found to be inducedbyChe-1 (data not shown).
Interestingly, among the Che-1-induced genes we identified the
TP53 oncosuppressor, whose role in DDR is well established
(Wahl and Carr, 2001), several p53 targets, e.g., p21, MDM2,
cyclin G2, P53DINP1 (Levine, 1997; Okamoto and Beach,
1994; Buckbinder et al., 1997; Okamura et al., 2001), and the
p53 coactivator Zac1 (Huang et al., 2001). These microarray
data were confirmed by semiquantitative RT-PCR (Figure 5A).
Furthermore, luciferase reporter assays showed a dose-
dependent activation of the human and mouse TP53 promoters
by Myc-Che-1 overexpression (Figures 5B and 5C).
To evaluate whether Che-1-mediated regulation of these
genes is preserved following DDR, HCT116 cells were depletedCANCER CELL DECEMBER 2006
A R T I C L EFigure 6. DNA damage promotes Che-1 recruit-
ment on p21 and Tp53 promoters
A: Increasing amounts of input samples (0.12,
0.25, 0.5, 1 ml) were used as template in PCR am-
plifications with specific primers for the indicated
promoters.
B: TCEs from HCT116 cells treated (+) or not (2)
with 1 mM Dox for 2 hr were subjected to ChIP
using anti-Che-1 Ab. Immunoprecipitates from
each sample were analyzed by PCR and a sam-
ple representing linear amplification (0.2–0.4 ml)
of the total input chromatin (Input) was included
in the PCRs as a control. Additional control in-
cluded a precipitation performed with non-
specific IgGs.
C: HCT116 cells were transfected with Myc-
Che-1 or Myc-Che-1S4A and treated (+) or not
(2) with 1 mM Dox for 2 hr. TCEs were subjected
to ChIP with anti-Myc Ab.
D: Equal amounts of RNA (RNA input) from
HCT116 transfected with the indicated expres-
sion vectors were analyzed by RT-PCR (25–30
cycles) for the expression of the indicated genes.
E: HCT116 cells were transiently transfected with
1 mg of TP53 promoter luciferase reporter and,
where indicated, with 1 mg of Myc empty vector
(control), Myc-Che-1, and Myc-Che-1S4A expres-
sion vectors. Lower panels, the expression levels
of Myc tagged Che-1 were assayed by WB
with anti-Myc Ab. Error bars indicate SD.
F: TCEs from HCT116 cells treated for the indi-
cated times with 1 mM Dox were immunoprecip-
itated with anti-p65 Ab and analyzed by WB with
the indicated Abs.
G: HCT116 cells were transfected with WT Myc-
Che-1 or Myc-Che-1S4A mutant. At 48 hr post-
transfection, cells were treated with 1 mM Dox
for 1 hr. TCEs were immunoprecipitated with
anti-p65 or anti-Myc Abs and analyzed by WB
with the indicated Abs.
H: HCT116 cells were transiently transfected with
Smart-Pool siRNA (si Control) or p65 siRNA (si p65)
and 48 hr later treated, where indicated, with
1 mM Dox for 2 hr. Then, cells were subjected
to ChIP using anti-Che-1 Ab or no IgGs.
I: HCT116 cells were transiently transfected with
1 mg of the human TP53 promoter luciferase
reporter, Smart-Pool siRNA (2) or p65 siRNA (+),
and Myc-Che-1, where indicated. Error bars
indicate SD.of Che-1 expression by siRNA (Figure 5D, uppermost panel) and
tested by RT-PCR in the presence or absence of Dox. As ex-
pected, Dox treatment did not increase Che-1 mRNA levels,
confirming that DDR regulates Che-1 only at the posttransla-
tional level (Figure 5D, uppermost panel). Che-1 depletion signif-
icantly inhibited transcription of the TP53 gene and all the other
genes identified in the microarray both in basal condition and
upon Dox treatment (Figure 5D and Figure S3D), supporting a
role of Che-1 in their transcriptional regulation. The inhibition
of p53 and p21 expression was also verified at the protein level
(Figure 5D, lowest panels). Indeed, despite the strong and well
characterized p53 stabilization induced by posttranslational
modifications in DDR, time course analysis showed that Che-1
depletion significantly delayed p53 accumulation (Figure 5E),
strongly indicating that Che-1 contributes to p53 induction. In
addition, time course analyses of Tet-induced and -uninduced
NIH3T3 cells treated with Dox confirmed that Che-1 affects
p53 expression (Figure S3A), and comparable results wereCANCER CELL DECEMBER 2006obtained when Myc-Che-1-overexpressing HCT116 cells were
treated with Dox (Figure S3B).
Finally, we compared the effect of wild-type Che-1 and the
nonphosphorylatable Che-1S4A mutant on p53 and p21 expres-
sion in the absence or presence of Dox. The exogenous expres-
sion of either Che-1 protein in the absence of Dox increased
the expression of p53 and p21 to a similar extent. However,
upon Dox treatment, only the wild-type Che-1, which can be
phosphorylated and stabilized, further and strongly increased
p53 and p21 expression (Figure 5F), indicating that the phos-
phorylation of Che-1 contributes to the activation of these
genes.
DNA damage promotes Che-1 recruitment on the TP53
and p21 promoters
Che-1 can be immunoprecipitatedwith the chromatin of E2F tar-
get genes during the G1/S transition (Bruno et al., 2002). To eval-
uatewhether Che-1 is present on the TP53 and p21 promoters in479
A R T I C L EFigure 7. Che-1 is involved in G2/M checkpoint maintenance
A: NIH3T3 cells induced (+Tet) or not (2Tet) were treated with or without 0.5 mM Dox for 24 hr. Cells were then fixed and stained with propidium iodide (PI) and
analyzed for DNA content.
B: Cell-cycle profiles of2Tet and +Tet NIH3T3 cells treated with 1 mM Dox for the indicated times. Profiles were determined by flow cytometry, which monitored
phosphorylation of histone H3 at Ser 10 (H3-S10-P), and DNA content by PI staining.
C: Top: NIH3T3 cells induced (+Tet) or not (2Tet) were treated with 1 mM Dox. TCEs were analyzed by WB with the indicated Abs. Bottom: Cdc2/Cyclin B1 com-
plex was immunoprecipitated with anti-cyclin B1 Ab and assayed for kinase activity using histone H1 substrate (see Experimental Procedures). The amount of
Cdc2 protein in the immunocomplexes was assessed by WB.
D: FACS profile of untransfected, GFP-siRNA-, and Che-1-siRNA-transfected 293 cells either untreated or subjected to IR (6 Gy) and stained with PI at the
indicated times.480 CANCER CELL DECEMBER 2006
A R T I C L EDDR, chromatin immunoprecipitations (ChIP) were performed
analyzing the NF-kB-binding region of the TP53 promoter (Hellin
et al., 1998; Pei et al., 1999) and the Sp1-binding regions of the
p21 promoter (Di Padova et al., 2003). As shown in Figure 6B,
ChIPs carried out under conditions of linear amplification (Fig-
ure 6A) revealed that the amount of Che-1 physically associated
with the TP53 and p21 promoters was barely detectable in nor-
mal proliferating conditions but drastically increased after Dox
treatment. Interestingly, a concomitant reduction of the amount
of Che-1 on the promoters of E2F target genes Dhfr and cyclin A
was observed, indicating that in DDR, Che-1 is displaced from
E2F target genes and recruited on the p21 and TP53 promoters
(Figure S3C). To evaluate whether the recruitment of Che-1 on
the TP53 promoter is mediated by ATM/ATR and Chk2 phos-
phorylation, HCT116 cells expressing Myc-Che-1 wild-type or
the Myc-Che-1S4A mutant were treated with Dox and subjected
toChIPwith anti-MycAb. The amount ofMyc-Che-1 on theTP53
promoter was strongly increased by Dox treatment, whereas
Myc-Che-1S4A was only barely detectable on this promoter in
both untreated and Dox-treated cells (Figure 6C). Conversely,
Myc-Che-1S4A was found associated to DHFR promoter, and
DNA damage displaced it to a lesser extent than Myc-Che-1
wild-type (Figure S3C). These results were confirmed when
Luc reporter of TP53 promoter was transfected into HCT116
cells with Myc-Che-1 or Myc-Che-1S4A. Indeed, the mutant
form of Che-1 did not activate TP53 transcription or Luc reporter
of TP53 promoter (Figures 6D and 6E), while it did activate the
E2F-target genes as well as the wild-type Che-1 (data not
shown).
Next, we tried to identify the mechanism(s) that allows Che-1
to target the TP53 promoter in DDR, and to determine whether
this function is regulated by Che-1 phosphorylation. Che-1
does not directly bind DNA (Fanciulli et al., 2000); therefore, we
investigated whether this molecule could form new interactions
with specific transcription factors in DDR. NF-kB binds the
TP53 promoter in DDR and regulates its activation (Hellin et al.,
1998; Pei et al., 1999); thus, we tested whether Che-1 and the
NF-kB p65 subunit can physically and functionally interact. As
shown in Figure 6F, coimmunoprecipitation of Che-1 with anti-
p65 Ab demonstrated increased amounts of Che-1 associated
to p65 after DNA damage. To test whether Che-1 phosphoryla-
tion was required for this interaction, coimmunoprecipitation
experiments were performed with HCT116 cells transfected
with Myc-tag empty vector, Myc-Che-1, or Myc-Che-1S4A and
treated with Dox. As shown in Figure 6G, Myc-Che-1 strongly
interactedwith p65whereasMyc-Che-1S4A did not bind this pro-
tein, indicating that Che-1 phosphorylation regulates Che-1/p65
interaction. Next, we tested whether p65 recruits Che-1 on the
TP53 promoter by ChIP analysis performed after DNA damage
in the presence or absence of p65-specific siRNA (Figure 6H).
The amount of Che-1 on the TP53 promoter strongly decreased
in the absence of p65 (Figure 6H). Furthermore, upon p65 deple-
tion, Che-1 did not activate TP53 transcription (Figure 6I). Taken
together, these observations strongly suggest that Che-1
phosphorylation in DDR can regulate protein-protein inter-
actions and confer promoter specificity.CANCER CELL DECEMBER 2006Che-1 is involved in the maintenance of the G2/M
checkpoint
Based on the results we obtained thus far, we asked whether
Che-1 is involved in the regulation ofG1/S andG2/Mcheckpoints
in response toDox treatment. TheNIH3T3cells that conditionally
express humanChe-1were employed. The Tet-induced, Che-1-
overexpressing cells exhibited a cell-cycle profile with a strong
G1 depletion and a concomitant G2/M accumulation (Figure 7A),
suggesting that Che-1 is involved in the G2/M transition check-
point. Consistently Che-1-overexpressing cells showed a
marked reduction in the levels of Ser10-phosphorylated H3 his-
tone, a typicalmitosismarker (Wei et al., 1999) (Figure 7B), and of
Cdc25Cphosphatase, a dual specificphosphatasewhoseactiv-
ity is essential for entry intomitosis (Dunphy, 1994) (Figure 7C), as
well as increasedamounts ofCdc2-Tyr15phosphorylation, a key
target of Cdc25C (Morla et al., 1989), correlated with a reduced
Cdc2 kinase activity (Figure 7C).
To further confirm the involvement of Che-1 in the G2/M
checkpoint, 293 cells were transfected with shRNA-pSuper
vectors silencing Che-1 or GFP and exposed to IR followed by
cell-cycle analysis. Both Che-1-depleted and control cells (un-
transfected or GFP shRNA transfected) exhibited a G2 arrest;
however, at later time points (24 hr) most of the Che-1-depleted
cells entered G1 while controls remained arrested in G2 (Fig-
ure 7D), indicating a failure of the Che-1-depleted cells to main-
tain the G2 arrest. In addition, Che-1 overexpression induced
in HCT116 and HCT116 p532/2 cells produced an increase of
G2/M accumulation only in the p53-proficient cells (Figures 7E
and 7F), indicating the p53-dependance of this phenomenon.
Indeed, although the p532/2 cells have a completely different
checkpoint activation by Dox treatment, as expected (Bunz
et al., 1998), Che-1 overexpression was not able to modify their
cell-cycle profile (Figure 7F).
Finally, we tested whether Che-1 overexpression can cause
DNA damage by itself. Myc-Che-1 or empty expression vectors
were transfected into HCT116 cells, and the levels of phosphor-
ylated histone H2AX were examined in the absence of drug. As
shown in Figure 7G, Che-1 did not affect phosphorylation of his-
tone H2AX, indicating that Che-1 overexpression does not
cause replication stress that activates DDR. Taken together,
these results strongly support an involvement of Che-1 in the
maintenance of the G2/M checkpoint in DDR.
Che-1 depletion increases sensitivity to anticancer
agents
In DDR, Che-1 is stabilized by its phosphorylation and contrib-
utes to the G2/M checkpoint by p53 and p21 activation. There-
fore, we askedwhether Che-1 expression affects tumor cell sen-
sitivity to DNA-damaging drugs. HCT116 cells were transfected
with wild-type Che-1 or the nonphosphorylatable Che-1S4A mu-
tant and treated with Dox. Wild-type Che-1 strongly protected
cells from apoptosis, whereas the mutant was significantly less
effective (Figures 8A and 8B), indicating that Che-1 phosphory-
lation is required for its antiapoptotic activity. Notably, Che-1
overexpression did not protect HCT116 p532/2 cells (Figure 8C),
supporting the requirement of p53 for Che-1 antiapoptoticE and F: p53+/+ (E) or p532/2 (F) HCT116 cells were treated with or without 0.5 mM Dox for 24 hr. Top: Cells were fixed, stained with PI, and analyzed for DNA
content. Bottom: TCEs were blotted and analyzed with the indicated Abs.
G: WB of HCT116 cells transfected either with Myc-tag empty vector or Myc-Che-1.481
A R T I C L EFigure 8. Che-1 depletion sensitizes tumor cells to anticancer drugs
A: Top: HCT116 cells were transiently transfected with Myc-tag empty vector, Myc-Che-1, and Myc-Che-1S4A expression vectors. At 48 hr posttransfection, cells
were treated with 1 mM Dox for 12 hr. After 7 days, parallel plates were stained with methylene blue. Bottom: expression levels of Myc-Che-1 by WB with anti-
Myc Ab.
B and C: Colony-formation assay performed with p53+/+ (B) and p532/2 (C) HCT116 cells transfected with the indicated plasmids, exposed to the indicated
doses of Dox for 12 hr, and evaluated 7 days later. The clonogenic assays were performed in triplicate. Error bars indicate SD.
D: Top: HCT116 cells were transiently transfected with siRNA GFP or siRNA Che-1 and 48 hr later treated, where indicated, with sublethal doses of Dox or DDP for
12 hr. After 7 days cells were treated as in A. Bottom: expression level of Che-1 and a-tubulin were assayed by WB.482 CANCER CELL DECEMBER 2006
A R T I C L Eactivity. Conversely, Che-1 depletion by siRNA strongly in-
creased Dox cytotoxicity (Figure 8F) and induced apoptosis in
HCT116 cells treated with sublethal doses of Dox or DDP (Fig-
ure 8D). In addition, Che-1 inhibition reverted chemoresistance
in colon cancer LoVo DX and ovarian cancer c13 cells, resistant
to Dox and DDP, respectively (Figure 8E). Comparable results
were obtained with other Dox-resistant cells (breast cancer
MCF7 and melanoma M14; data not shown). In agreement with
previous results (Figure 8C), Che-1 depletion did not significantly
affect HCT116 p532/2 cells (Figure 8GandFigure S4A). Next, we
evaluatedwhether normalHFFswere sensitized toDoxbyChe-1
removal. Che-1 depletion strongly reduces HFF proliferation
(Bruno et al., 2002) and protected these cells from drug treat-
ment (Figure 8H). Taken together, these results indicate that
Che-1 defends cells from apoptosis in a p53-dependent manner
and that its depletion sensitizes tumor but not normal cells to
anticancer drugs.
Discussion
Eukaryotic cells’ DDR involves the activation of ATM/ATR ki-
nases that can specifically target p53 for phosphorylation, either
directly or indirectly through Chk2 and Chk1 kinases. These p53
modifications are required for inhibiting p53 degradation by
MDM2 and for allowing additional p53-activating posttransla-
tional modifications. Here, we show that ATM and Chk2 can
also modulate TP53 and p21 gene transcription through phos-
phorylation of the transcription regulator Che-1. Moreover, we
show that Che-1 contributes to the maintenance of the G2/M
checkpoint and that its downregulation by siRNA sensitizes
cancer cells to chemotherapy.
Our results show that Che-1 is stabilized in vitro and in vivo in
response to either physical and chemical genotoxic agents. This
induction is very rapid (within 45 min from damage) and is
mediated by posttranslational modifications. In vivo phosphate
metabolic labeling and anti-phospho-Che-1 Ab revealed that
Che-1 is strongly phosphorylated in DDR. In addition, we found
that Che-1’s half-life is regulated by the proteasome and
that specific phosphorylations protect the protein from
degradation.
We show that ATM and Chk2 kinases can phosphorylate
Che-1, increasing its half-life and contributing to activation of
p53 and p21 at the transcriptional level and to maintenance of
the G2/M checkpoint. Although multiple phosphorylations are
necessary for a complete phenotype, our results showed that
both ATM and Chk2 alone posses measurable effects on
Che-1 stabilization. Furthermore, we demonstrate that other
kinases involved in DDR, such as ATR and Chk1, phosphorylate
Che-1, thus suggesting that this modification is a general event
following DNA damage.
We have previously reported that Che-1 is involved in the
activation of E2F-target gene promoters and cell proliferation
affecting Rb growth suppression (Fanciulli et al., 2000; Bruno
et al., 2002), and that Che-1 is found on the E2F target gene pro-
moters during the G1/S transition (Bruno et al., 2002). Here weCANCER CELL DECEMBER 2006show that treatment with Dox increases the selective recruit-
ment of Che-1 on the TP53 and p21 promoters. Moreover,
Che-1 phosphorylation by ATM and Chk2 is required for Che-
1 recruitment on the TP53 promoter, whereas it does not affect
Che-1 recruitment onto E2F-target gene promoters (data not
shown). It has been described that DNA damage activation of
the TP53 promoter is mediated by NF-kB (Hellin et al., 1998;
Pei et al., 1999). Accordingly, we show here that Dox treatment
markedly increases Che-1 levels at the NF-kB site of the human
TP53 promoter. Che-1 interacts with the NF-kB subunit p65; this
interaction is mediated by Che-1 phosphorylation and is in-
creased in DDR. Therefore, it is possible that posttranslational
modifications of Che-1 mediate its interactions with transcrip-
tion factors or cofactors and in such way regulate Che-1’s pres-
ence onto specific promoters.
Che-1 was found to activate p53 transcription in the absence
of DNA damage (Figures 5A–5C), but even in this case p53
transactivation requires Che-1 phosphorylation (Figures 6D
and 6E). Consistent with these findings, Che-1 phosphorylation
is also slightly detectable even in absence of Dox treatment
(Figure 1G), probably by intrinsic DNA damage occurring during
DNA replication or by another mechanism(s) to be character-
ized. Thus, it is possible to speculate a model where Che-1 is re-
quired for the basal state of p53 expression, and that this effect
is preserved and reinforced in DDR.
We show that Che-1 is involved in the maintenance of the
G2/M checkpoint, at least in part, by activation of the TP53
and p21 genes. The products of these geneswere characterized
as key proteins in the regulation of both G1 and G2 checkpoints
(Wahl and Carr, 2001; Boulaire et al., 2000); therefore, the Che-1
effects in the G2/M checkpoint might be paradoxical. However,
a way to reconcile these data is to point out that one of the
key functions of Che-1 is to promote E2F gene transcription
by displacing HDAC1 from Rb, weakening in this way p53’s
effects on the G1 checkpoint. On the other hand, evidence impli-
cates p53 and p21 in controlling entry into mitosis when cells
enter G2 with damaged DNA (Bunz et al., 1998; Taylor and Stark,
2001).
We recently showed that Che-1 is downregulated in several
tumors and that Che-1 overexpression arrests the growth of hu-
man colon carcinoma cell lines through a p53-independent
induction of p21 (Di Padova et al., 2003). This observation fits
with a model where Che-1 is considered a component of DDR
that protects cells from early progression of human cancer
(Bartkova et al., 2005; Gorgoulis et al., 2005). Furthermore, the
early embryonic lethality of Che-1-deficient mice (Thomas
et al., 2000) suggests that Che-1 as well as ATR and Chk1 could
be required for normal progression through the cell cycle, even
in absence of cellular stress.
DNA-damaging agents are the mainstays of cancer therapy
and have achieved impressive clinical results. However, they
are often plagued by various limitations, such as elevated sys-
temic toxicity or drug resistance. Activation of DNA damage
checkpoints promotes DNA repair and cell survival, but it might
also reduce the effectiveness of chemotherapeutics. Therefore,E: Top: LoVo DX (Dox-resistant) and c13 (DDP-resistant) cells were transiently transfected with siRNA GFP or siRNA Che-1 and grown in the presence of 0.5 mM
Dox (LoVo DX) or 5 mg/ml DDP (c13). After 7 days cells were treated as in A. Bottom: expression level of Che-1 and a-tubulin were assayed by WB.
F–H: HCT116 (F), HCT116 p532/2 (G), and HFF (H) cells were transfected with siGFP (siRNA control) or siChe-1 and subjected to colony-formation assays after
Dox treatments as described in B. Error bars indicate SD.483
A R T I C L Ethe cytotoxicity of unspecific DNA-damaging agents that nor-
mally induce cell-cycle arrest in tumor cells could be enhanced
by combining themwith checkpoint inhibitors (Zhou and Bartek,
2004). In agreement with these considerations, our studies con-
firm that Che-1 is an antiapoptotic factor (Page et al., 1999) and
demonstrate that Che-1 phosphorylation is required for this
activity. More importantly, they show that Che-1 inhibition inten-
sifies the cytotoxicity of anticancer drugs that damage the DNA
and, in such way, can revert chemoresistance of several tumor
cell lines. Conversely, in normal cells, with more intact cell-cycle
control, the lack of Che-1 function in DDR is better tolerated. The
latter observation strengthens the notion that Che-1 can be con-
sidered a valid target for the design of drugs that can enhance
the efficacy of chemotherapeutic drugs in cancer patients with-
out cytotoxicity on their own.
Experimental procedures
Cell culture, transfections, and analysis
p53+/+ and p532/2 HCT116 and MEF, 293, and NIH3T3 expressing Tet-con-
ditional Che-1 (Bruno et al., 2002) were grown in DMEM supplemented with
10% fetal bovine serum (FBS); HFF and ATM 2/2 human fibroblasts (AT) (a
kind gift from Dr. L. Wood) with 15% FBS; HCT15 cells were grown in
RPMI plus 15% FBS. U2OS, LoVo DX (Dox-resistant cells), and c13 (DDP-re-
sistant cells) (kindly provided by Dr. Howell) were grown in RPMI plus 10%
FBS. HCT15 cells stably transfected with either wild-type Chk2 or kd Chk2
were kindly provided by Dr. J. Chen. Flow cytometric analyses were per-
formed using FACScalibur (Becton-Dickinson, San Jose, CA). Data analyses
were performed using Cell Quest (BDIS) and ModFit LT (Verity Software
House, Topsham,ME). Transfections were carried out by BES-calcium phos-
phate precipitation as described (Fanciulli et al., 2000) or by Lipofectamine
Plus (Invitrogen). Colony-forming efficiency assays and luciferase assays
were performed as previously described (Fanciulli et al., 2000). Data are pre-
sented as mean6 SD of three independent experiments performed in dupli-
cate. Doxorubicin, caffeine, and cycloheximide were purchased from Sigma,
whereas MG132 was purchased from Calbiochem. Clinical-grade DDP (Cis-
platino Teva) was obtained from Teva Pharma.
Recombinant plasmids and proteins
The Myc-tagged Che-1 and its deletions were described (Fanciulli et al.,
2000). Che-1 deletions were cloned into the pGEX4T3 vector (Pharmacia)
to produce Glutathione-S-transferase (GST) fusion proteins. Plasmids ex-
pressing bacterial recombinant GST-p53 and 63His-p53 were produced
by cloning the complete ORF of mouse p53 into pGEX4T1 (Pharmacia) or
pQE30 (QIAGEN) bacterial expression vectors, respectively. Flag-ATM
and Flag-ATM kd expression vectors were kind gifts from Dr. Y. Shiloh and
Dr. M.B. Kastan, respectively. Flag-ATR and Flag-ATR kd expression vectors
were kindly provided by Dr. Okamoto. Myc-Chk2, Myc-Chk2 kd, and Flag-
Chk1 were a gift from Dr. J. Bartek. The human and mouse p53 pro-
moters fused to luciferase reporter were kindly provided by Dr. M. Oren
and Dr. V. Rotter. GST-tagged proteins were produced as described
(Fanciulli et al., 2000). Mutagenesis of Myc-Che-1 was performed using the
QuikChange Mutagenesis system (Stratagene).
Antibodies
The following rabbit polyclonal Abs were used: anti-Che-1 (Fanciulli et al.,
2000), p53, p65, Cdc2, (Tyr-15)-P-Cdc2, Cdc25C, (sc-6243, sc-372, sc-954,
sc-7989, sc-327; Santa Cruz), Cyclin B1 (Calbiochem), and anti-(Ser10)-P-
histone H3 (Upstate). Mouse monoclonal Abs anti-Myc 9e10 (Invitrogen),
Flag M2 (Sigma), anti-P-histone H2AX and Chk2 (Upstate), ATM (Delia
et al., 2000), a-tubulin, and human p21 (sc-8035 and sc-6246; Santa Cruz)
were also used.
Immunoprecipitations and WB analysis
TCEs were immunoprecipitated by standard procedures. WBwere prepared
by standard procedures, and immunoreactivity was detected by ECL
chemioluminescence reaction (Amersham). Densitometric analyses of484immunoblots and RT-PCR were performed using Quantity-One software
(Bio-Rad). Ratios were calculated by the following formula:
intensity sample=intensity a-tubulin ðor GAPDHÞ
intensity control=intensity a-tubulin ðor GAPDHÞ:
Metabolic labeling
Cells were incubated for 2 hr with 0.5 mCi/ml [32P] inorganic phosphate
(Amersham) in phosphate-free medium (Sigma), in presence of absence of
Dox, before immunoprecipitation of Che-1 with the indicated Abs. For
pulse-chase analysis, cells were incubated for 1 hr with or without Dox and
then with 0.5 mCi/ml [35S] methionine (Amersham) in DMEM without methio-
nine (Sigma) for 20 min. Then, cells were extensively washed, incubated in
DMEM medium, and collected at the indicated times. TCEs were immuno-
precipitated with anti-Che-1 Ab.
Kinase assays
Immunoprecipitated Flag-ATM, Flag-ATR, Myc-Chk2, and Flag-Chk1 were
incubated with GST fusion proteins in kinase buffer (see Supplemental
Data) for 30min at 30C. Kinase assays for Cdc2were carried out by incubat-
ing immunoprecipitated Cdc2/cyclin B1 complex and 1 mg of Histone H1
(Sigma) as substrate in Cdc2 kinase buffer. Reactions were stopped by add-
ing 53 sample buffer, and proteins were resolved by SDS-PAGE. Dried gels
were analyzed by phosphoimager (Bio-Rad).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed using anti-
Che-1 polyclonal Ab as described (Bruno et al., 2002). In each experiment,
signal linearity was ensured by amplifying increasing amounts of template
DNA (see Figure 6A). Generally, DNA representing 0.005% to 0.01% of the
total chromatin sample (input) or 1% to 10% of the immunoprecipitated
was amplified using promoter-specific primers whose sequences are pro-
vided in Supplemental Data. Immunoprecipitations with no specific immuno-
globulins (Santa Cruz) were performed as negative control.
siRNA
The 22 nucleotide siRNA duplexes corresponding to nucleotides 191–212
of human Che-1 sequence and to nucleotides 122–143 of the negative
control green fluorescent protein (GFP) sequence were synthesized by
Xeragon. RNA interference was performed as previously described (Bruno
et al., 2002). siRNA-mediated interference experiments of ATM, Chk2, and
p65 expression in HCT116 or HFF cells were performed by transfecting
SMART pool specific or nonspecific control pool double-stranded RNA
oligonucleotides (Dharmacon) using Lipofectamine Plus. For maintenance
of G2 arrest, Che-1 siRNA and GFP siRNA were inserted into pSUPER
(Oligoengine).
Supplemental data
Supplemental Data include four figures and Supplemental Experimental
Procedures and are available at http://www.cancercell.org/cgi/content/full/
10/6/473/DC1/.
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